Logo Prima Biomed

Welcome to the Newsroom

06 October 2016

Prima Abstracts accepted for Poster Presentation at ESMO Symposium on Immuno-Oncology

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces that an abstract for each of its two clinical trials for IMP321 has been accepted for Poster presentation (display) during the European Society for Medical Oncology (ESMO) Symposium on ‘Immuno-Oncology - Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies’ from 4-6 November 2016 in Lausanne, Switzerland.